Table 2.
Frequency of new development of cardiovascular outcomes over 20 years of follow-up in the epidemiological cohort (n = 4626).
| New cardiovascular diagnosis | Any N (%;p)a |
Alk N (%;p) |
Ab N (%;p) |
Antib N (%;p) |
Antim N (%;p) |
Endo N (%;p) |
Enz N (%;p) |
Mit N (%;p) |
Other N (%;p) |
|---|---|---|---|---|---|---|---|---|---|
| Atrial Fibrillation | 224 (12; 0.004) |
111 (11; 0.359) |
46 (12; 0.373) |
60 (12; 0.406) |
79 (11; 0.417) |
69 (11; 0.995) |
41 (15; 0.015) |
81 (12; 0.142) |
83 (12; 0.292) |
| Coronary Artery Disease | 267 (15; 0.192) |
136 (14; 0.825) |
58 (15; 0.441) |
83 (16; 0.097) |
101 (15; 0.448) |
105 (16; 0.0568) |
47 (17; 0.088) |
94 (14; 0.726) |
100 (14; 0.759) |
| Cardiomegaly | 254 (14; 0.0001) |
145 (15; 0.0004) |
65 (17; 0.0008) |
89 (17; <0.0001) |
110 (16; 0.0001) |
101 (16; 0.0009) |
47 (17; 0.0031) |
109 (16; <0.0001) |
100 (14; 0.026) |
| Cardiomyopathy | 190 (10; <0.0001) |
104 (11; 0.0001) |
53 (14; <0.0001) |
59 (11; 0.006) |
70 (10; 0.007) |
61 (9; 0.0759) |
51 (19; <0.0001) |
65 (10; 0.0245) |
85 (12; 0.0001) |
| Heart Failure | 281 (15; <0.0001) |
155 (16; 0.0002) |
71 (18; 0.0002) |
83 (16; 0.008) |
114 (17; 0.0004) |
111 (17; 0.0001) |
58 (21; <0.0001) |
105 (16; 0.0045) |
100 (14; 0.149) |
| Peripheral Artery Disease | 2594 (14; 0.092) |
134 (14; 0.489) |
60 (16; 0.134) |
68 (13; 0.935) |
94 (14; 0.640) |
114 (17; 0.0003) |
35 (13; 0.884) |
101 (15; 0.077) |
74 (10; 0.023) |
| Stroke | 166 (9; 0.206) |
89 (9; 0.362) |
41 (11; 0.102) |
58 (11; 0.0135) |
70 (10; 0.074) |
69 (11; 0.031) |
26 (10; 0.501) |
69 (10; 0.046) |
65 (9; 0.431) |
Ab: Antibodies; Alk: Alkylating agents; Antib: Antineoplastic antibodies (anthracyclines); Antim: Antimetabolites; Endo: Endocrine therapies; Enz: Enzyme inhibitors; Mitotic Inhibitors; Other: Other pharmacologic cancer therapies.
a
Percentage of individuals treated with cancer therapy who developed cardiovascular outcome or comorbidity after cancer diagnosis; compared to individuals treated with cancer therapy who did not develop cardiovascular outcome or comorbidity after cancer diagnosis; bold indicates statistical significance using a p-value<0.005, due to multiple comparisons.